Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide combined with camrelizumab for RCCEP in advanced non-small cell lung cancer
ChiCTR2300078905Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Dec 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of thalidomide and camrelizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoints: Incidence of RCCEP and RCCEP response rate. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
thalidomidecamrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300078905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078905.